Last reviewed · How we verify
Dexamethasone Ophthalmic implant
At a glance
| Generic name | Dexamethasone Ophthalmic implant |
|---|---|
| Also known as | ozurdex implant |
| Sponsor | Frank A. Bucci, Jr., M.D. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (PHASE1, PHASE2)
- Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients (PHASE4)
- Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant
- Dexamethasone Implant for Retinal Detachment in Uveal Melanoma (PHASE1)
- Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant (NA)
- Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion (PHASE2, PHASE3)
- A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China
- Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamethasone Ophthalmic implant CI brief — competitive landscape report
- Dexamethasone Ophthalmic implant updates RSS · CI watch RSS
- Frank A. Bucci, Jr., M.D. portfolio CI